Literature DB >> 1325474

Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.

A Rösler1, A Bélanger, F Labrie.   

Abstract

17 beta-Hydroxysteroid dehydrogenase (17 beta HSD) deficiency is a rare cause of male pseudohermaphroditism, but is a frequent disorder among a highly inbred Arab population in the Gaza strip. Affected individuals are born and reared as females until puberty, when marked virilization occurs, leading in many cases to the spontaneous adoption of a male gender role. To investigate the mechanisms and site(s) of androgen production, we determined the gonadal and extragonadal steroid patterns in two postpubertal male pseudohermaphroditism patients, who were castrated and reared as females. Before castration, both patients had very high plasma levels of androstenedione (delta 4-A), normal or moderately low levels of testosterone (T), and significantly elevated delta 4-A/T ratios (P less than 0.01). Dihydrotestosterone (DHT) levels were normal or high, while the DHT/T ratios were lower than normal (P less than 0.01), suggesting enhanced 5 alpha-reductase activity. These abnormalities were much more severe in spermatic venous blood. 17 beta HSD deficiency was also found in the delta 5-pathway, by high dehydroepiandrosterone (DHEA) levels and very high dehydroxyepiandrosterone/delta 5-androstenediol (DHEA/delta 5-diol) ratios, and in peripheral tissue metabolites, by very high androsterone glucuronide/3 alpha-androstanediol glucuronide ratios (P less than 0.01). The estrogen pathway was also impaired (P less than 0.01), even though both estrone and estradiol levels were elevated. Gonadectomy significantly reduced all androgens and estrogens (P less than 0.01), but when compared to 42 castrated controls, both patients had lower delta 4-A and higher T levels. The delta 4-A/T ratio was lower than that in controls, indicating normal to enhanced extragonadal 17 beta HSD activity. A similar pattern was observed in the delta 5- and estrogen pathways. DHT levels were within normal limits, and 3 alpha-diol was moderately decreased. These data suggest that testicular 17 beta HSD activity is under a different genetic control from that in extragonadal tissues. Affected males lack the testicular enzyme, but their extragonadal 17 beta HSD activity is normal or enhanced. Together with enhanced 5 alpha-reductase activity, this represents a highly efficient compensatory mechanism for androgen and estrogen production after puberty.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325474     DOI: 10.1210/jcem.75.3.1325474

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.

Authors:  Dwight R Stickney; Clarence N Ahlem; Elizabeth Morgan; Christopher L Reading; Nanette Onizuka; James M Frincke
Journal:  Am J Transl Res       Date:  2011-04-12       Impact factor: 4.060

Review 2.  Germ cell neoplasia in situ complicating 17β-hydroxysteroid dehydrogenase type 3 deficiency.

Authors:  Lisal J Folsom; Mariam Hjaige; Jiayan Liu; Erica A Eugster; Richard J Auchus
Journal:  Mol Cell Endocrinol       Date:  2018-11-30       Impact factor: 4.102

Review 3.  Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency.

Authors:  M F Faienza; L Giordani; M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

4.  17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite.

Authors:  Lindsay M Mains; Babak Vakili; Yves Lacassie; Stefan Andersson; Annika Lindqvist; John A Rock
Journal:  Fertil Steril       Date:  2007-05-16       Impact factor: 7.329

5.  Complexities of gender assignment in 17β-hydroxysteroid dehydrogenase type 3 deficiency: is there a role for early orchiectomy?

Authors:  Janet Chuang; Amy Vallerie; Lesley Breech; Howard M Saal; Shumyle Alam; Peggy Crawford; Meilan M Rutter
Journal:  Int J Pediatr Endocrinol       Date:  2013-09-12

6.  46,XY disorder of sex development due to 17-beta hydroxysteroid dehydrogenase type 3 deficiency: a plea for timely genetic testing.

Authors:  Chelsey Grimbly; Oana Caluseriu; Peter Metcalfe; Mary M Jetha; Elizabeth T Rosolowsky
Journal:  Int J Pediatr Endocrinol       Date:  2016-06-15

Review 7.  Disorder of Sex Development Due to 17-Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: A Case Report and Review of 70 Different HSD17B3 Mutations Reported in 239 Patients.

Authors:  Catarina I Gonçalves; Josianne Carriço; Margarida Bastos; Manuel C Lemos
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

8.  The novel founder homozygous V225M mutation in the HSD17B3 gene causes aberrant splicing and XY-DSD.

Authors:  Sharon Zeligson; Eran Lavi; Tehila Klopstock; David Zangen; Reeval Segel; Floris Levy-Khademi; Boris Chertin; Carmit Avnon-Ziv; Abdulsalam Abulibdeh; Paul Renbaum; Tzvia Rosen; Shira Perlberg-Bengio; Fouad Zahdeh; Doron M Behar; Ephrat Levy-Lahad
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

9.  Severe Undervirilisation in a 46,XY Case Due to a Novel Mutation in HSD17B3 Gene.

Authors:  Ayfer Alikaşifoğlu; Doğuş Vurallı; Olaf Hiort; Nazlı Gönç; Alev Özön; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.